| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 49 | 2025 | 533 | 8.700 |
Why?
|
| Listeriosis | 50 | 2017 | 86 | 7.260 |
Why?
|
| Listeria monocytogenes | 55 | 2020 | 93 | 6.760 |
Why?
|
| Microbiota | 24 | 2023 | 411 | 5.100 |
Why?
|
| Intestines | 23 | 2024 | 419 | 5.070 |
Why?
|
| Monocytes | 24 | 2017 | 222 | 5.010 |
Why?
|
| Anti-Bacterial Agents | 38 | 2024 | 803 | 4.920 |
Why?
|
| Bacteria | 28 | 2025 | 497 | 4.730 |
Why?
|
| Bacterial Infections | 17 | 2019 | 185 | 4.080 |
Why?
|
| Klebsiella pneumoniae | 9 | 2024 | 39 | 4.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 38 | 2023 | 916 | 4.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 46 | 2020 | 607 | 3.890 |
Why?
|
| Immunity, Innate | 25 | 2016 | 437 | 3.320 |
Why?
|
| Klebsiella Infections | 7 | 2024 | 30 | 3.290 |
Why?
|
| Aspergillus fumigatus | 12 | 2011 | 18 | 3.290 |
Why?
|
| Mice | 145 | 2024 | 11993 | 3.170 |
Why?
|
| Colitis | 10 | 2024 | 251 | 3.090 |
Why?
|
| Feces | 38 | 2023 | 339 | 3.080 |
Why?
|
| Antigen Presentation | 27 | 2016 | 215 | 3.030 |
Why?
|
| Gram-Positive Bacterial Infections | 10 | 2019 | 50 | 3.030 |
Why?
|
| Animals | 189 | 2024 | 27783 | 3.000 |
Why?
|
| Clostridium Infections | 11 | 2024 | 125 | 2.960 |
Why?
|
| Enterococcus faecium | 8 | 2019 | 33 | 2.840 |
Why?
|
| Antigens, Bacterial | 29 | 2016 | 136 | 2.500 |
Why?
|
| Histocompatibility Antigens Class I | 25 | 2005 | 202 | 2.480 |
Why?
|
| Mice, Inbred C57BL | 64 | 2024 | 3303 | 2.440 |
Why?
|
| Gastrointestinal Tract | 12 | 2022 | 191 | 2.440 |
Why?
|
| Vancomycin Resistance | 6 | 2019 | 18 | 2.430 |
Why?
|
| Inflammation | 19 | 2021 | 998 | 2.350 |
Why?
|
| T-Lymphocytes, Cytotoxic | 30 | 2011 | 320 | 2.260 |
Why?
|
| Dendritic Cells | 22 | 2016 | 450 | 2.110 |
Why?
|
| Aspergillosis | 12 | 2011 | 41 | 2.070 |
Why?
|
| Probiotics | 6 | 2022 | 88 | 2.020 |
Why?
|
| T-Lymphocytes | 24 | 2016 | 1237 | 2.000 |
Why?
|
| Vancomycin-Resistant Enterococci | 7 | 2019 | 14 | 1.990 |
Why?
|
| Myeloid Differentiation Factor 88 | 9 | 2012 | 49 | 1.930 |
Why?
|
| Immunity, Mucosal | 10 | 2020 | 70 | 1.920 |
Why?
|
| Bacterial Toxins | 13 | 2017 | 115 | 1.890 |
Why?
|
| Metagenome | 9 | 2023 | 109 | 1.890 |
Why?
|
| Receptors, CCR2 | 15 | 2017 | 33 | 1.860 |
Why?
|
| Immunologic Memory | 22 | 2020 | 171 | 1.820 |
Why?
|
| Drug Resistance, Bacterial | 10 | 2020 | 76 | 1.790 |
Why?
|
| Enterocolitis, Pseudomembranous | 4 | 2016 | 52 | 1.770 |
Why?
|
| Bacteremia | 11 | 2023 | 103 | 1.740 |
Why?
|
| Dysbiosis | 11 | 2024 | 82 | 1.730 |
Why?
|
| Intestinal Mucosa | 14 | 2019 | 809 | 1.670 |
Why?
|
| Genome, Bacterial | 7 | 2025 | 150 | 1.620 |
Why?
|
| Lymphocyte Activation | 30 | 2016 | 759 | 1.600 |
Why?
|
| T-Lymphocyte Subsets | 15 | 2003 | 277 | 1.580 |
Why?
|
| RNA, Ribosomal, 16S | 23 | 2022 | 255 | 1.520 |
Why?
|
| Bile Acids and Salts | 6 | 2022 | 72 | 1.500 |
Why?
|
| Vancomycin | 9 | 2019 | 74 | 1.480 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 3 | 2024 | 10 | 1.410 |
Why?
|
| Enterococcus | 7 | 2019 | 35 | 1.410 |
Why?
|
| Immune System | 4 | 2017 | 98 | 1.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 14 | 2016 | 453 | 1.370 |
Why?
|
| Antibiosis | 4 | 2024 | 9 | 1.320 |
Why?
|
| Virulence Factors | 4 | 2019 | 114 | 1.300 |
Why?
|
| Metabolome | 5 | 2023 | 52 | 1.280 |
Why?
|
| H-2 Antigens | 19 | 2005 | 58 | 1.280 |
Why?
|
| Humans | 145 | 2025 | 91074 | 1.240 |
Why?
|
| Cell Movement | 12 | 2013 | 793 | 1.190 |
Why?
|
| Graft vs Host Disease | 12 | 2020 | 362 | 1.180 |
Why?
|
| Bacterial Proteins | 18 | 2024 | 906 | 1.170 |
Why?
|
| Spleen | 15 | 2009 | 433 | 1.150 |
Why?
|
| Host-Pathogen Interactions | 9 | 2017 | 237 | 1.150 |
Why?
|
| Symbiosis | 7 | 2021 | 130 | 1.130 |
Why?
|
| Disease Resistance | 3 | 2015 | 18 | 1.090 |
Why?
|
| Mice, Inbred BALB C | 39 | 2018 | 1102 | 1.060 |
Why?
|
| Bacteriocins | 3 | 2024 | 12 | 1.030 |
Why?
|
| Immunocompromised Host | 6 | 2020 | 143 | 1.030 |
Why?
|
| Mice, Knockout | 21 | 2020 | 2053 | 1.010 |
Why?
|
| Flagellin | 4 | 2021 | 18 | 1.000 |
Why?
|
| Colon | 4 | 2019 | 522 | 0.990 |
Why?
|
| Toll-Like Receptors | 6 | 2014 | 92 | 0.960 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2019 | 410 | 0.950 |
Why?
|
| Neutrophils | 4 | 2015 | 315 | 0.940 |
Why?
|
| Hematologic Neoplasms | 7 | 2016 | 355 | 0.940 |
Why?
|
| Antigens, Ly | 6 | 2014 | 37 | 0.930 |
Why?
|
| Opportunistic Infections | 3 | 2015 | 60 | 0.930 |
Why?
|
| Heat-Shock Proteins | 11 | 2008 | 183 | 0.920 |
Why?
|
| Genetic Variation | 5 | 2024 | 1384 | 0.910 |
Why?
|
| Carbapenems | 4 | 2024 | 12 | 0.910 |
Why?
|
| Disease Susceptibility | 3 | 2015 | 200 | 0.910 |
Why?
|
| Spores, Fungal | 4 | 2009 | 18 | 0.900 |
Why?
|
| Adaptive Immunity | 4 | 2015 | 167 | 0.900 |
Why?
|
| Epitopes | 16 | 2005 | 255 | 0.880 |
Why?
|
| Cross Infection | 5 | 2021 | 151 | 0.880 |
Why?
|
| Disease Models, Animal | 14 | 2024 | 2416 | 0.870 |
Why?
|
| Disease | 2 | 2022 | 90 | 0.870 |
Why?
|
| Fecal Microbiota Transplantation | 7 | 2022 | 68 | 0.860 |
Why?
|
| Cytokines | 10 | 2015 | 817 | 0.860 |
Why?
|
| Transplantation, Homologous | 21 | 2021 | 1004 | 0.860 |
Why?
|
| Chemokine CCL2 | 5 | 2017 | 47 | 0.850 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2020 | 24 | 0.840 |
Why?
|
| Respiratory Tract Infections | 4 | 2019 | 108 | 0.830 |
Why?
|
| Female | 81 | 2024 | 47186 | 0.820 |
Why?
|
| Th1 Cells | 5 | 2016 | 166 | 0.810 |
Why?
|
| Chemotaxis, Leukocyte | 5 | 2010 | 38 | 0.810 |
Why?
|
| Toll-Like Receptor 5 | 3 | 2012 | 10 | 0.810 |
Why?
|
| Therapeutics | 1 | 2022 | 12 | 0.800 |
Why?
|
| Intestinal Diseases | 2 | 2014 | 79 | 0.790 |
Why?
|
| Epitopes, T-Lymphocyte | 14 | 2009 | 88 | 0.770 |
Why?
|
| Intestine, Small | 5 | 2016 | 299 | 0.750 |
Why?
|
| DNA, Bacterial | 10 | 2024 | 246 | 0.750 |
Why?
|
| Virulence | 5 | 2024 | 282 | 0.740 |
Why?
|
| Clostridiales | 2 | 2020 | 18 | 0.730 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2021 | 55 | 0.710 |
Why?
|
| Macrophages | 13 | 2017 | 589 | 0.700 |
Why?
|
| Enterobacter cloacae | 1 | 2020 | 8 | 0.690 |
Why?
|
| Proteus mirabilis | 1 | 2020 | 4 | 0.690 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2020 | 86 | 0.690 |
Why?
|
| Mycobacterium tuberculosis | 5 | 2016 | 201 | 0.690 |
Why?
|
| Lactococcus lactis | 1 | 2019 | 6 | 0.670 |
Why?
|
| Spores, Bacterial | 2 | 2016 | 18 | 0.670 |
Why?
|
| Proteome | 1 | 2021 | 142 | 0.670 |
Why?
|
| Hemolysin Proteins | 11 | 2008 | 34 | 0.660 |
Why?
|
| Bacterial Physiological Phenomena | 3 | 2018 | 42 | 0.660 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2017 | 23 | 0.650 |
Why?
|
| Biological Therapy | 2 | 2017 | 47 | 0.640 |
Why?
|
| beta-Lactam Resistance | 1 | 2019 | 11 | 0.640 |
Why?
|
| Phylogeny | 8 | 2025 | 1220 | 0.640 |
Why?
|
| Survival Analysis | 10 | 2020 | 1500 | 0.630 |
Why?
|
| Bacteroidetes | 4 | 2024 | 39 | 0.620 |
Why?
|
| Metronidazole | 2 | 2015 | 26 | 0.620 |
Why?
|
| Cell Differentiation | 14 | 2014 | 1564 | 0.620 |
Why?
|
| Interleukin-10 | 3 | 2016 | 157 | 0.610 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 320 | 0.600 |
Why?
|
| Antifungal Agents | 4 | 2008 | 123 | 0.600 |
Why?
|
| Cytotoxicity, Immunologic | 12 | 2011 | 217 | 0.600 |
Why?
|
| Communicable Diseases | 2 | 2016 | 65 | 0.600 |
Why?
|
| Diarrhea | 6 | 2021 | 178 | 0.590 |
Why?
|
| Mice, Transgenic | 22 | 2016 | 1589 | 0.570 |
Why?
|
| beta-Glucans | 2 | 2008 | 7 | 0.570 |
Why?
|
| Carbohydrates | 1 | 2017 | 48 | 0.560 |
Why?
|
| Bacterial Adhesion | 1 | 2017 | 85 | 0.560 |
Why?
|
| Immunodominant Epitopes | 7 | 2003 | 20 | 0.550 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 52 | 0.550 |
Why?
|
| Peptides | 15 | 2005 | 660 | 0.540 |
Why?
|
| Lithocholic Acid | 1 | 2016 | 2 | 0.530 |
Why?
|
| Firmicutes | 1 | 2015 | 15 | 0.510 |
Why?
|
| N-Formylmethionine | 4 | 2005 | 5 | 0.510 |
Why?
|
| Fungi | 2 | 2006 | 67 | 0.510 |
Why?
|
| Gastroenteritis | 2 | 2016 | 26 | 0.500 |
Why?
|
| Kidney Transplantation | 7 | 2019 | 863 | 0.500 |
Why?
|
| Histocompatibility Antigens Class II | 7 | 2016 | 167 | 0.500 |
Why?
|
| Neutrophil Infiltration | 2 | 2012 | 29 | 0.500 |
Why?
|
| Signal Transduction | 14 | 2016 | 3442 | 0.490 |
Why?
|
| Bone Marrow | 4 | 2019 | 446 | 0.480 |
Why?
|
| Lymph Nodes | 7 | 2009 | 554 | 0.460 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 91 | 0.460 |
Why?
|
| Bacteroidaceae | 2 | 2016 | 3 | 0.460 |
Why?
|
| Cell Line | 16 | 2017 | 2506 | 0.460 |
Why?
|
| Neoplasms | 7 | 2023 | 3053 | 0.460 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 151 | 0.460 |
Why?
|
| Peptide Fragments | 8 | 2003 | 465 | 0.450 |
Why?
|
| Cell Proliferation | 8 | 2016 | 1695 | 0.450 |
Why?
|
| Lung Diseases | 1 | 2016 | 276 | 0.450 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2009 | 91 | 0.450 |
Why?
|
| Interleukin-23 | 3 | 2016 | 57 | 0.440 |
Why?
|
| Bradyrhizobium | 1 | 2013 | 3 | 0.440 |
Why?
|
| Pulmonary Aspergillosis | 2 | 2009 | 4 | 0.420 |
Why?
|
| Flow Cytometry | 13 | 2016 | 695 | 0.420 |
Why?
|
| Fetal Blood | 1 | 2013 | 93 | 0.420 |
Why?
|
| Antigens, T-Independent | 2 | 2004 | 4 | 0.420 |
Why?
|
| Down-Regulation | 4 | 2021 | 520 | 0.410 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2012 | 29 | 0.410 |
Why?
|
| Lymphotoxin-alpha | 1 | 2012 | 44 | 0.410 |
Why?
|
| Pneumonia | 2 | 2022 | 185 | 0.410 |
Why?
|
| Homeostasis | 5 | 2018 | 429 | 0.400 |
Why?
|
| Cecum | 1 | 2012 | 73 | 0.400 |
Why?
|
| Receptors, Chemokine | 3 | 2009 | 31 | 0.400 |
Why?
|
| Male | 52 | 2021 | 43249 | 0.400 |
Why?
|
| Nisin | 2 | 2024 | 4 | 0.390 |
Why?
|
| Genomics | 4 | 2024 | 793 | 0.390 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2012 | 19 | 0.390 |
Why?
|
| Clindamycin | 1 | 2011 | 15 | 0.390 |
Why?
|
| Proteins | 5 | 2016 | 800 | 0.390 |
Why?
|
| Ileum | 1 | 2012 | 168 | 0.380 |
Why?
|
| Interferon-gamma | 8 | 2011 | 448 | 0.380 |
Why?
|
| Echinocandins | 3 | 2008 | 5 | 0.380 |
Why?
|
| Langerhans Cells | 2 | 2018 | 14 | 0.380 |
Why?
|
| Cell Division | 11 | 2004 | 692 | 0.370 |
Why?
|
| Pancreatitis-Associated Proteins | 5 | 2016 | 15 | 0.370 |
Why?
|
| Monocyte-Macrophage Precursor Cells | 2 | 2014 | 4 | 0.360 |
Why?
|
| Chemotaxis | 3 | 2020 | 73 | 0.360 |
Why?
|
| Butyrates | 3 | 2020 | 50 | 0.360 |
Why?
|
| Obesity | 2 | 2020 | 989 | 0.350 |
Why?
|
| Lung | 5 | 2016 | 1310 | 0.350 |
Why?
|
| Biodiversity | 6 | 2020 | 223 | 0.350 |
Why?
|
| Virus Diseases | 3 | 2019 | 101 | 0.350 |
Why?
|
| Ampicillin | 6 | 2020 | 15 | 0.340 |
Why?
|
| Cells, Cultured | 10 | 2009 | 2891 | 0.340 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 705 | 0.340 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 511 | 0.340 |
Why?
|
| Herpesvirus 4, Human | 5 | 2004 | 120 | 0.340 |
Why?
|
| Immunomodulation | 3 | 2015 | 58 | 0.340 |
Why?
|
| Lung Diseases, Fungal | 2 | 2006 | 18 | 0.330 |
Why?
|
| Membrane Proteins | 4 | 2012 | 1237 | 0.330 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2009 | 20 | 0.330 |
Why?
|
| Adult | 35 | 2021 | 27147 | 0.330 |
Why?
|
| Interleukins | 4 | 2016 | 132 | 0.330 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2009 | 51 | 0.320 |
Why?
|
| Influenza, Human | 2 | 2010 | 342 | 0.320 |
Why?
|
| Middle Aged | 33 | 2021 | 26555 | 0.320 |
Why?
|
| Base Sequence | 11 | 2013 | 2329 | 0.320 |
Why?
|
| Chemokines | 1 | 2009 | 74 | 0.320 |
Why?
|
| Bone Marrow Transplantation | 5 | 2018 | 286 | 0.310 |
Why?
|
| Asymptomatic Infections | 2 | 2019 | 17 | 0.310 |
Why?
|
| Escherichia coli | 3 | 2020 | 612 | 0.310 |
Why?
|
| Enteritis | 2 | 2015 | 21 | 0.310 |
Why?
|
| Immunity, Cellular | 5 | 2008 | 179 | 0.310 |
Why?
|
| Chemokine CCL7 | 1 | 2008 | 2 | 0.310 |
Why?
|
| Mycoses | 2 | 2006 | 46 | 0.310 |
Why?
|
| Risk Factors | 14 | 2019 | 5608 | 0.300 |
Why?
|
| Amino Acid Sequence | 14 | 2024 | 2077 | 0.300 |
Why?
|
| Germ-Free Life | 2 | 2019 | 78 | 0.300 |
Why?
|
| Sequence Analysis, DNA | 5 | 2024 | 872 | 0.300 |
Why?
|
| Oligopeptides | 2 | 2001 | 189 | 0.290 |
Why?
|
| Sepsis | 3 | 2021 | 330 | 0.290 |
Why?
|
| Carrier State | 2 | 2019 | 39 | 0.280 |
Why?
|
| Molecular Sequence Data | 15 | 2012 | 3031 | 0.280 |
Why?
|
| Respiratory Mucosa | 1 | 2007 | 88 | 0.280 |
Why?
|
| Bone Marrow Cells | 4 | 2009 | 263 | 0.270 |
Why?
|
| Kinetics | 10 | 2007 | 1548 | 0.270 |
Why?
|
| N-Acetylmuramoyl-L-alanine Amidase | 2 | 1997 | 11 | 0.270 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 2014 | 88 | 0.270 |
Why?
|
| Models, Animal | 5 | 2018 | 278 | 0.270 |
Why?
|
| Antigens | 2 | 2020 | 229 | 0.270 |
Why?
|
| Antigens, Differentiation | 2 | 2003 | 141 | 0.270 |
Why?
|
| Bacterial Vaccines | 3 | 2001 | 44 | 0.260 |
Why?
|
| Time Factors | 12 | 2017 | 5378 | 0.260 |
Why?
|
| Peptides, Cyclic | 2 | 2003 | 44 | 0.260 |
Why?
|
| Myocardium | 1 | 2009 | 579 | 0.260 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2017 | 493 | 0.260 |
Why?
|
| Pyrimidines | 2 | 2013 | 372 | 0.260 |
Why?
|
| Metabolomics | 2 | 2024 | 81 | 0.260 |
Why?
|
| Melanoma | 3 | 2016 | 475 | 0.260 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 391 | 0.250 |
Why?
|
| Immune Tolerance | 5 | 2014 | 350 | 0.250 |
Why?
|
| Cell Wall | 1 | 2006 | 70 | 0.250 |
Why?
|
| Lymphocyte Subsets | 3 | 2015 | 66 | 0.250 |
Why?
|
| Receptors, Immunologic | 2 | 2003 | 137 | 0.250 |
Why?
|
| Cysteine Endopeptidases | 4 | 1998 | 87 | 0.250 |
Why?
|
| Microbial Interactions | 3 | 2020 | 11 | 0.250 |
Why?
|
| Mouth | 2 | 2017 | 48 | 0.240 |
Why?
|
| Metagenomics | 3 | 2022 | 94 | 0.240 |
Why?
|
| Membrane Glycoproteins | 5 | 2002 | 434 | 0.240 |
Why?
|
| Hot Temperature | 1 | 2005 | 208 | 0.240 |
Why?
|
| Adoptive Transfer | 8 | 2011 | 170 | 0.240 |
Why?
|
| Ligands | 6 | 2018 | 453 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 3 | 2017 | 687 | 0.230 |
Why?
|
| Administration, Oral | 3 | 2020 | 673 | 0.220 |
Why?
|
| Amino Acids | 1 | 2024 | 250 | 0.220 |
Why?
|
| Lymphocyte Depletion | 8 | 2010 | 99 | 0.220 |
Why?
|
| Lymphocytes | 3 | 2016 | 470 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2009 | 2440 | 0.220 |
Why?
|
| Antigen-Presenting Cells | 4 | 2014 | 142 | 0.220 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.220 |
Why?
|
| Graft Rejection | 4 | 2019 | 1091 | 0.220 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 39 | 0.220 |
Why?
|
| Interleukin-2 | 1 | 2004 | 240 | 0.210 |
Why?
|
| DNA Contamination | 1 | 2023 | 1 | 0.210 |
Why?
|
| Survival Rate | 4 | 2017 | 1898 | 0.210 |
Why?
|
| Clone Cells | 7 | 2005 | 215 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1093 | 0.210 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 103 | 0.210 |
Why?
|
| Biomass | 1 | 2023 | 36 | 0.210 |
Why?
|
| Immunization | 5 | 2005 | 163 | 0.210 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 126 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2009 | 2375 | 0.210 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 852 | 0.210 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2019 | 100 | 0.210 |
Why?
|
| Triazoles | 1 | 2003 | 107 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 418 | 0.200 |
Why?
|
| Herpes Simplex | 1 | 2003 | 203 | 0.200 |
Why?
|
| Major Histocompatibility Complex | 3 | 2005 | 84 | 0.200 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2022 | 29 | 0.190 |
Why?
|
| DNA, Ribosomal | 2 | 2012 | 46 | 0.190 |
Why?
|
| Fetus | 1 | 2023 | 232 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 150 | 0.190 |
Why?
|
| Clostridium | 3 | 2017 | 24 | 0.190 |
Why?
|
| Gram-Positive Bacteria | 2 | 2019 | 18 | 0.190 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2013 | 175 | 0.190 |
Why?
|
| Tuberculosis | 3 | 2011 | 122 | 0.190 |
Why?
|
| Schistosomiasis haematobia | 1 | 2021 | 1 | 0.180 |
Why?
|
| Trypanosoma brucei brucei | 2 | 1991 | 4 | 0.180 |
Why?
|
| Molecular Epidemiology | 1 | 2021 | 54 | 0.180 |
Why?
|
| Schistosomiasis mansoni | 1 | 2021 | 9 | 0.180 |
Why?
|
| Proteomics | 1 | 2023 | 242 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 1404 | 0.180 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 35 | 0.180 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 270 | 0.180 |
Why?
|
| Streptomycin | 1 | 2020 | 5 | 0.180 |
Why?
|
| Aged | 18 | 2021 | 19574 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 163 | 0.180 |
Why?
|
| Lipopolysaccharides | 3 | 2011 | 296 | 0.180 |
Why?
|
| Cell Membrane Permeability | 1 | 2021 | 120 | 0.180 |
Why?
|
| CD11b Antigen | 3 | 2012 | 37 | 0.180 |
Why?
|
| Microbial Viability | 2 | 2020 | 33 | 0.180 |
Why?
|
| Propionates | 1 | 2020 | 33 | 0.180 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 603 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2022 | 4367 | 0.170 |
Why?
|
| Ovalbumin | 1 | 2020 | 109 | 0.170 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 397 | 0.170 |
Why?
|
| Ecosystem | 1 | 2024 | 369 | 0.170 |
Why?
|
| Health Promotion | 1 | 2022 | 164 | 0.170 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 1998 | 143 | 0.170 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2016 | 59 | 0.170 |
Why?
|
| Intra-Abdominal Fat | 1 | 2020 | 32 | 0.170 |
Why?
|
| Lactose | 1 | 2019 | 27 | 0.170 |
Why?
|
| Killer Cells, Natural | 4 | 2014 | 278 | 0.160 |
Why?
|
| beta-Lactamases | 1 | 2020 | 56 | 0.160 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 75 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2017 | 605 | 0.160 |
Why?
|
| Lectins, C-Type | 3 | 2011 | 86 | 0.160 |
Why?
|
| Stress, Physiological | 1 | 2021 | 237 | 0.160 |
Why?
|
| Enterobacteriaceae | 1 | 2018 | 22 | 0.160 |
Why?
|
| Nanotubes, Carbon | 1 | 2018 | 2 | 0.160 |
Why?
|
| Antigens, CD1 | 1 | 1999 | 37 | 0.160 |
Why?
|
| Amines | 1 | 2018 | 28 | 0.160 |
Why?
|
| Mutagenesis, Insertional | 1 | 2019 | 114 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 47 | 0.150 |
Why?
|
| Interleukin-17 | 2 | 2016 | 105 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1753 | 0.150 |
Why?
|
| DNA Transposable Elements | 1 | 2019 | 176 | 0.150 |
Why?
|
| Nutritional Support | 1 | 2018 | 16 | 0.150 |
Why?
|
| Specific Pathogen-Free Organisms | 3 | 2015 | 78 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 185 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2012 | 727 | 0.150 |
Why?
|
| Transcriptome | 2 | 2021 | 679 | 0.150 |
Why?
|
| Cathepsin B | 1 | 2017 | 12 | 0.150 |
Why?
|
| Metalloendopeptidases | 1 | 1997 | 44 | 0.150 |
Why?
|
| Biomarkers | 3 | 2020 | 1814 | 0.140 |
Why?
|
| Fatty Acids | 4 | 2023 | 141 | 0.140 |
Why?
|
| Peripheral Nerves | 1 | 2017 | 37 | 0.140 |
Why?
|
| Injections, Intravenous | 3 | 2003 | 238 | 0.140 |
Why?
|
| Keratinocytes | 1 | 2018 | 146 | 0.140 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 195 | 0.140 |
Why?
|
| Lipopeptides | 3 | 2008 | 19 | 0.140 |
Why?
|
| Macrophages, Alveolar | 2 | 2009 | 62 | 0.140 |
Why?
|
| Mice, Mutant Strains | 2 | 2008 | 231 | 0.140 |
Why?
|
| Models, Immunological | 2 | 2011 | 81 | 0.140 |
Why?
|
| CD40 Antigens | 3 | 2002 | 43 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2017 | 234 | 0.140 |
Why?
|
| Cytomegalovirus | 3 | 2007 | 84 | 0.130 |
Why?
|
| Pilot Projects | 5 | 2019 | 887 | 0.130 |
Why?
|
| Intestinal Polyps | 1 | 2016 | 27 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 33 | 0.130 |
Why?
|
| Celecoxib | 1 | 2016 | 31 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 430 | 0.130 |
Why?
|
| Daptomycin | 1 | 2016 | 3 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1182 | 0.130 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2016 | 8 | 0.130 |
Why?
|
| Cell Line, Tumor | 6 | 2019 | 2615 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2008 | 375 | 0.130 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 24 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 121 | 0.130 |
Why?
|
| Bifidobacterium | 1 | 2015 | 17 | 0.130 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2016 | 42 | 0.130 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 2024 | 219 | 0.130 |
Why?
|
| Communicable Disease Control | 1 | 2016 | 52 | 0.130 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 190 | 0.120 |
Why?
|
| Acute Disease | 3 | 2011 | 855 | 0.120 |
Why?
|
| Bacteroides | 1 | 2015 | 35 | 0.120 |
Why?
|
| Retrospective Studies | 11 | 2022 | 9400 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 140 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2016 | 108 | 0.120 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 2013 | 18 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 339 | 0.120 |
Why?
|
| Hospitalization | 1 | 2021 | 903 | 0.120 |
Why?
|
| Sialic Acids | 1 | 1994 | 18 | 0.120 |
Why?
|
| Virus Activation | 2 | 2007 | 42 | 0.120 |
Why?
|
| Immunization, Secondary | 4 | 2004 | 34 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2019 | 544 | 0.120 |
Why?
|
| Tumor Necrosis Factors | 1 | 2014 | 14 | 0.120 |
Why?
|
| Fucose | 1 | 2014 | 13 | 0.120 |
Why?
|
| Arthritis, Psoriatic | 1 | 2015 | 34 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 2347 | 0.120 |
Why?
|
| Antigens, Viral | 3 | 2008 | 146 | 0.120 |
Why?
|
| Vitamins | 1 | 2015 | 83 | 0.110 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2014 | 45 | 0.110 |
Why?
|
| Mice, Inbred C3H | 3 | 2001 | 371 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 2 | 2007 | 153 | 0.110 |
Why?
|
| Cytosol | 2 | 2009 | 193 | 0.110 |
Why?
|
| Bacteroidaceae Infections | 1 | 2013 | 1 | 0.110 |
Why?
|
| Prevotella | 1 | 2013 | 3 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 982 | 0.110 |
Why?
|
| Microbial Consortia | 1 | 2014 | 14 | 0.110 |
Why?
|
| Prognosis | 3 | 2020 | 3825 | 0.110 |
Why?
|
| Species Specificity | 4 | 2012 | 690 | 0.110 |
Why?
|
| Transplantation | 1 | 2014 | 38 | 0.110 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 57 | 0.110 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 75 | 0.110 |
Why?
|
| Tacrolimus | 1 | 2015 | 371 | 0.110 |
Why?
|
| Epithelium | 1 | 2014 | 323 | 0.110 |
Why?
|
| B7-H1 Antigen | 1 | 2015 | 281 | 0.110 |
Why?
|
| Glycoproteins | 1 | 1994 | 236 | 0.110 |
Why?
|
| Colony Count, Microbial | 4 | 2017 | 46 | 0.110 |
Why?
|
| Ecology | 1 | 2013 | 78 | 0.110 |
Why?
|
| Anisoles | 1 | 2013 | 5 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2006 | 316 | 0.110 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2013 | 9 | 0.110 |
Why?
|
| Phenotype | 3 | 2014 | 2480 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 245 | 0.100 |
Why?
|
| Herpes Genitalis | 2 | 2003 | 41 | 0.100 |
Why?
|
| Periodontitis | 1 | 2012 | 7 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1750 | 0.100 |
Why?
|
| Protective Factors | 3 | 2018 | 23 | 0.100 |
Why?
|
| Autoantigens | 4 | 2005 | 132 | 0.100 |
Why?
|
| Infection Control | 1 | 2014 | 124 | 0.100 |
Why?
|
| Chemokine CXCL1 | 1 | 2012 | 9 | 0.100 |
Why?
|
| Gene Products, env | 2 | 2002 | 5 | 0.100 |
Why?
|
| Gene Products, gag | 2 | 2002 | 12 | 0.100 |
Why?
|
| AIDS Vaccines | 2 | 2002 | 10 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 252 | 0.100 |
Why?
|
| RNA, Bacterial | 1 | 2013 | 111 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2014 | 296 | 0.100 |
Why?
|
| Enterocolitis | 1 | 2012 | 13 | 0.100 |
Why?
|
| HLA-A2 Antigen | 2 | 2003 | 30 | 0.100 |
Why?
|
| Integrin alpha Chains | 1 | 2012 | 16 | 0.100 |
Why?
|
| Lymphocyte Count | 6 | 2004 | 99 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2012 | 84 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 3 | 2001 | 1049 | 0.100 |
Why?
|
| Mice, Inbred NOD | 3 | 2020 | 200 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 854 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2004 | 55 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 1991 | 48 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 153 | 0.100 |
Why?
|
| Antibodies, Blocking | 1 | 2011 | 22 | 0.100 |
Why?
|
| Diet | 1 | 2015 | 447 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2019 | 79 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 888 | 0.090 |
Why?
|
| Haplotypes | 2 | 2008 | 639 | 0.090 |
Why?
|
| Tumor Escape | 1 | 2011 | 51 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 157 | 0.090 |
Why?
|
| Antigens, CD34 | 2 | 2009 | 161 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2003 | 111 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2011 | 103 | 0.090 |
Why?
|
| Computational Biology | 1 | 2015 | 556 | 0.090 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2011 | 12 | 0.090 |
Why?
|
| Ribotyping | 2 | 2021 | 11 | 0.090 |
Why?
|
| Interleukin-15 | 2 | 2002 | 76 | 0.090 |
Why?
|
| Biological Evolution | 2 | 2019 | 988 | 0.090 |
Why?
|
| Neutropenia | 1 | 2011 | 216 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2013 | 491 | 0.090 |
Why?
|
| Epidermis | 2 | 2018 | 102 | 0.090 |
Why?
|
| Mast-Cell Sarcoma | 2 | 2003 | 15 | 0.090 |
Why?
|
| HIV Infections | 1 | 2020 | 865 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 303 | 0.090 |
Why?
|
| CD11c Antigen | 2 | 2016 | 13 | 0.090 |
Why?
|
| Pregnancy | 2 | 2023 | 3079 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1144 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1806 | 0.090 |
Why?
|
| Th17 Cells | 1 | 2011 | 86 | 0.090 |
Why?
|
| Child, Preschool | 8 | 2010 | 3790 | 0.090 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 75 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2012 | 471 | 0.080 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2000 | 43 | 0.080 |
Why?
|
| Child | 9 | 2010 | 7273 | 0.080 |
Why?
|
| Recurrence | 1 | 2013 | 1170 | 0.080 |
Why?
|
| Uterus | 1 | 2011 | 222 | 0.080 |
Why?
|
| Cell Count | 1 | 2010 | 200 | 0.080 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2009 | 23 | 0.080 |
Why?
|
| beta 2-Microglobulin | 2 | 2000 | 24 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 997 | 0.080 |
Why?
|
| Carcinoma | 1 | 2013 | 438 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2009 | 51 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 1016 | 0.080 |
Why?
|
| Receptors, IgG | 1 | 2009 | 54 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2018 | 212 | 0.080 |
Why?
|
| DNA Primers | 3 | 1999 | 546 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1877 | 0.080 |
Why?
|
| Angiotensin II | 1 | 2009 | 93 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 106 | 0.080 |
Why?
|
| Substrate Specificity | 3 | 2004 | 363 | 0.080 |
Why?
|
| Metapneumovirus | 1 | 2008 | 3 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 4 | 2014 | 925 | 0.080 |
Why?
|
| Paramyxoviridae Infections | 1 | 2008 | 5 | 0.080 |
Why?
|
| Staining and Labeling | 2 | 2001 | 173 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2009 | 167 | 0.080 |
Why?
|
| Chemokine CXCL2 | 1 | 2008 | 16 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2009 | 108 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 591 | 0.080 |
Why?
|
| Cell Separation | 4 | 2010 | 200 | 0.080 |
Why?
|
| Candida albicans | 1 | 2008 | 31 | 0.080 |
Why?
|
| Evolution, Molecular | 2 | 2025 | 859 | 0.080 |
Why?
|
| Allografts | 2 | 2020 | 192 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2020 | 960 | 0.070 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2008 | 3 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 434 | 0.070 |
Why?
|
| Norovirus | 2 | 2019 | 13 | 0.070 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 483 | 0.070 |
Why?
|
| Multienzyme Complexes | 2 | 1998 | 64 | 0.070 |
Why?
|
| Adenovirus Infections, Human | 1 | 2007 | 3 | 0.070 |
Why?
|
| Antibodies, Bacterial | 2 | 1999 | 100 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 282 | 0.070 |
Why?
|
| Protein Folding | 2 | 2001 | 293 | 0.070 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 1998 | 108 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 1295 | 0.070 |
Why?
|
| Organophosphonates | 1 | 2007 | 52 | 0.070 |
Why?
|
| Lectins | 1 | 2007 | 84 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2018 | 2904 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 2 | 2021 | 35 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2007 | 490 | 0.070 |
Why?
|
| Cytosine | 1 | 2007 | 131 | 0.070 |
Why?
|
| Brefeldin A | 2 | 1997 | 10 | 0.070 |
Why?
|
| Cyclopentanes | 2 | 1997 | 27 | 0.060 |
Why?
|
| Adolescent | 9 | 2010 | 9411 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 243 | 0.060 |
Why?
|
| Islets of Langerhans | 2 | 2000 | 553 | 0.060 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2005 | 5 | 0.060 |
Why?
|
| Antigens, Fungal | 1 | 2005 | 6 | 0.060 |
Why?
|
| Protein Conformation | 2 | 1999 | 903 | 0.060 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Infant | 6 | 2008 | 3204 | 0.060 |
Why?
|
| Antibodies, Fungal | 1 | 2005 | 6 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 272 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2006 | 91 | 0.060 |
Why?
|
| Endoplasmic Reticulum | 2 | 1998 | 258 | 0.060 |
Why?
|
| Vesicular stomatitis Indiana virus | 2 | 2002 | 16 | 0.060 |
Why?
|
| Inhalation Exposure | 1 | 2005 | 31 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 2005 | 342 | 0.060 |
Why?
|
| Graft Survival | 2 | 2018 | 918 | 0.060 |
Why?
|
| Brain | 1 | 2016 | 2327 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 1995 | 27 | 0.060 |
Why?
|
| Gene Expression | 1 | 2010 | 1313 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6847 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 279 | 0.060 |
Why?
|
| Vaccination | 3 | 2002 | 281 | 0.060 |
Why?
|
| Liver | 4 | 2010 | 1222 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2005 | 109 | 0.060 |
Why?
|
| Precipitin Tests | 2 | 1995 | 111 | 0.060 |
Why?
|
| Insulinoma | 1 | 2005 | 37 | 0.060 |
Why?
|
| Viridans Streptococci | 1 | 2004 | 1 | 0.060 |
Why?
|
| WT1 Proteins | 1 | 2004 | 20 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1465 | 0.060 |
Why?
|
| Citrobacter rodentium | 2 | 2014 | 14 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2004 | 55 | 0.060 |
Why?
|
| CD40 Ligand | 2 | 2002 | 71 | 0.060 |
Why?
|
| Models, Biological | 1 | 2011 | 1771 | 0.060 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2024 | 39 | 0.060 |
Why?
|
| Glycosylation | 2 | 2014 | 128 | 0.060 |
Why?
|
| Alleles | 4 | 2005 | 1138 | 0.060 |
Why?
|
| Intubation, Intratracheal | 1 | 2005 | 148 | 0.060 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 988 | 0.060 |
Why?
|
| Receptors, CCR5 | 1 | 2004 | 17 | 0.060 |
Why?
|
| Autocrine Communication | 1 | 2004 | 21 | 0.060 |
Why?
|
| Anaerobiosis | 1 | 2024 | 22 | 0.060 |
Why?
|
| Mice, Congenic | 2 | 2000 | 12 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2019 | 320 | 0.060 |
Why?
|
| Viral Load | 2 | 2004 | 145 | 0.060 |
Why?
|
| Stem Cells | 1 | 2006 | 381 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 285 | 0.060 |
Why?
|
| Virus Latency | 1 | 2004 | 33 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2024 | 113 | 0.050 |
Why?
|
| Voriconazole | 1 | 2003 | 18 | 0.050 |
Why?
|
| HIV | 1 | 2003 | 49 | 0.050 |
Why?
|
| Amniotic Fluid | 1 | 2023 | 30 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2003 | 210 | 0.050 |
Why?
|
| Binding, Competitive | 2 | 1993 | 146 | 0.050 |
Why?
|
| Integrin alphaXbeta2 | 1 | 2002 | 2 | 0.050 |
Why?
|
| Cloning, Molecular | 3 | 1999 | 646 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1994 | 270 | 0.050 |
Why?
|
| Trichosporon | 1 | 2002 | 2 | 0.050 |
Why?
|
| Fluconazole | 1 | 2002 | 11 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2003 | 151 | 0.050 |
Why?
|
| Amphotericin B | 1 | 2002 | 36 | 0.050 |
Why?
|
| Feedback | 1 | 2003 | 137 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 532 | 0.050 |
Why?
|
| Herpesvirus 2, Human | 1 | 2002 | 45 | 0.050 |
Why?
|
| Respiration | 1 | 2024 | 269 | 0.050 |
Why?
|
| Protozoan Infections | 1 | 2001 | 3 | 0.050 |
Why?
|
| CD28 Antigens | 1 | 2002 | 89 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2001 | 53 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 65 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3716 | 0.050 |
Why?
|
| Immunity | 1 | 2022 | 141 | 0.050 |
Why?
|
| Listeria | 1 | 2001 | 3 | 0.050 |
Why?
|
| Mice, Inbred Strains | 3 | 1999 | 309 | 0.050 |
Why?
|
| Schistosoma haematobium | 1 | 2021 | 1 | 0.050 |
Why?
|
| Placenta | 1 | 2023 | 186 | 0.050 |
Why?
|
| United States | 3 | 2021 | 7188 | 0.050 |
Why?
|
| Culture Media | 1 | 2001 | 148 | 0.050 |
Why?
|
| Schistosoma mansoni | 1 | 2021 | 17 | 0.050 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2001 | 30 | 0.050 |
Why?
|
| HIV-1 | 1 | 2002 | 163 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 8436 | 0.050 |
Why?
|
| HLA-B8 Antigen | 1 | 2000 | 3 | 0.050 |
Why?
|
| HLA-B7 Antigen | 1 | 2000 | 7 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 743 | 0.040 |
Why?
|
| Young Adult | 4 | 2017 | 6502 | 0.040 |
Why?
|
| Biopolymers | 1 | 2000 | 27 | 0.040 |
Why?
|
| Mammals | 1 | 2023 | 244 | 0.040 |
Why?
|
| Amoxicillin | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cell Survival | 1 | 2003 | 984 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2000 | 137 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2000 | 177 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 1998 | 284 | 0.040 |
Why?
|
| Mice, Inbred DBA | 2 | 2005 | 150 | 0.040 |
Why?
|
| Bacteriuria | 1 | 2019 | 10 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2020 | 143 | 0.040 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1999 | 10 | 0.040 |
Why?
|
| Lyme Disease | 1 | 1999 | 9 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 1999 | 130 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2019 | 34 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 386 | 0.040 |
Why?
|
| Gene Library | 1 | 1999 | 133 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 156 | 0.040 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 17 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2033 | 0.040 |
Why?
|
| L-Selectin | 1 | 1999 | 17 | 0.040 |
Why?
|
| Skin | 1 | 2002 | 586 | 0.040 |
Why?
|
| Thymus Gland | 1 | 1999 | 197 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2000 | 511 | 0.040 |
Why?
|
| ADAM17 Protein | 1 | 2018 | 9 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 1993 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 309 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2000 | 378 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 116 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2000 | 791 | 0.040 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 3 | 2005 | 73 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 163 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2001 | 570 | 0.040 |
Why?
|
| Dimerization | 1 | 1998 | 143 | 0.040 |
Why?
|
| Schwann Cells | 1 | 2017 | 34 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2018 | 499 | 0.040 |
Why?
|
| CD8 Antigens | 2 | 2000 | 82 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 2020 | 0.040 |
Why?
|
| Protein Binding | 4 | 2004 | 1508 | 0.040 |
Why?
|
| Incidence | 3 | 2007 | 1599 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 351 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 280 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2018 | 170 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 456 | 0.030 |
Why?
|
| Lysine | 1 | 2018 | 181 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2000 | 516 | 0.030 |
Why?
|
| Time | 1 | 2016 | 77 | 0.030 |
Why?
|
| Cilastatin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Imipenem | 1 | 2016 | 2 | 0.030 |
Why?
|
| Verrucomicrobia | 1 | 2016 | 2 | 0.030 |
Why?
|
| Piperacillin | 1 | 2016 | 8 | 0.030 |
Why?
|
| Penicillanic Acid | 1 | 2016 | 12 | 0.030 |
Why?
|
| Transfection | 2 | 1995 | 910 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2785 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 1997 | 117 | 0.030 |
Why?
|
| Perforin | 2 | 2011 | 55 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 368 | 0.030 |
Why?
|
| Caliciviridae Infections | 1 | 2016 | 10 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1996 | 57 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2016 | 72 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2015 | 13 | 0.030 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 205 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2016 | 60 | 0.030 |
Why?
|
| Apoptosis | 2 | 2018 | 1723 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 75 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 1996 | 171 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1131 | 0.030 |
Why?
|
| Mast Cells | 1 | 1995 | 94 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 570 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 821 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 272 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1713 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1196 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 499 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 126 | 0.030 |
Why?
|
| Imidazoles | 1 | 2016 | 139 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 1994 | 5 | 0.030 |
Why?
|
| RANK Ligand | 1 | 2015 | 10 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1994 | 35 | 0.030 |
Why?
|
| Proteobacteria | 1 | 2014 | 6 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 209 | 0.030 |
Why?
|
| Glycoside Hydrolases | 1 | 1994 | 17 | 0.030 |
Why?
|
| Neuraminidase | 1 | 1994 | 47 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2016 | 191 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2014 | 9 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2014 | 2 | 0.030 |
Why?
|
| Anorexia | 1 | 2014 | 28 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 355 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 86 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2014 | 82 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 56 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 56 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 2022 | 0.030 |
Why?
|
| Eating | 1 | 2014 | 168 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 147 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2014 | 128 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 426 | 0.030 |
Why?
|
| Porphyromonas gingivalis | 1 | 2012 | 1 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2016 | 383 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 323 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1892 | 0.030 |
Why?
|
| CD13 Antigens | 1 | 1992 | 5 | 0.030 |
Why?
|
| Aminopeptidases | 1 | 1992 | 14 | 0.030 |
Why?
|
| Carboxypeptidases | 1 | 1992 | 35 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 2003 | 218 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2012 | 69 | 0.020 |
Why?
|
| Psoriasis | 1 | 2015 | 245 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1991 | 125 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2016 | 399 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 112 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2011 | 49 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 29 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2005 | 429 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 111 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 1991 | 42 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1935 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 1858 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2002 | 448 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 292 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1991 | 227 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 596 | 0.020 |
Why?
|
| Rabbits | 1 | 1991 | 642 | 0.020 |
Why?
|
| Vaccinia virus | 2 | 2002 | 19 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2011 | 281 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 324 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1991 | 794 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 10 | 0.020 |
Why?
|
| New York City | 1 | 2008 | 61 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1559 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1493 | 0.020 |
Why?
|
| Recombination, Genetic | 2 | 2002 | 447 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2018 | 2348 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 278 | 0.020 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2006 | 10 | 0.020 |
Why?
|
| Stroke | 1 | 2016 | 1006 | 0.020 |
Why?
|
| Graft vs Tumor Effect | 1 | 2006 | 25 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2006 | 176 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 1169 | 0.020 |
Why?
|
| Mutation | 1 | 1997 | 4203 | 0.020 |
Why?
|
| CD11 Antigens | 1 | 2005 | 15 | 0.020 |
Why?
|
| Regeneration | 1 | 2006 | 157 | 0.020 |
Why?
|
| Genes, Wilms Tumor | 1 | 2004 | 6 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2005 | 49 | 0.010 |
Why?
|
| DNA | 1 | 1990 | 1313 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2005 | 339 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 1265 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2682 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2004 | 260 | 0.010 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2004 | 40 | 0.010 |
Why?
|
| Temperature | 1 | 2004 | 404 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 207 | 0.010 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2002 | 6 | 0.010 |
Why?
|
| Plasmodium yoelii | 1 | 2002 | 4 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 21 | 0.010 |
Why?
|
| Diphtheria Toxin | 1 | 2002 | 22 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2510 | 0.010 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2002 | 3 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 97 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 154 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 189 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2002 | 92 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 101 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1216 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 2001 | 23 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 560 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 183 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 657 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 289 | 0.010 |
Why?
|
| Peritoneum | 1 | 2001 | 57 | 0.010 |
Why?
|
| Influenza A virus | 1 | 2001 | 172 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 565 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2001 | 111 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 804 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2000 | 135 | 0.010 |
Why?
|
| Receptors, NK Cell Lectin-Like | 1 | 1999 | 5 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 1999 | 23 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1999 | 73 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1999 | 52 | 0.010 |
Why?
|
| COS Cells | 1 | 1999 | 167 | 0.010 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 1999 | 5 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 1999 | 54 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2000 | 191 | 0.010 |
Why?
|
| Solubility | 1 | 1999 | 184 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1999 | 279 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 1263 | 0.010 |
Why?
|
| Borrelia Infections | 1 | 1997 | 2 | 0.010 |
Why?
|
| Nematode Infections | 1 | 1997 | 4 | 0.010 |
Why?
|
| Pneumocystis Infections | 1 | 1997 | 3 | 0.010 |
Why?
|
| Leishmaniasis | 1 | 1997 | 4 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 1997 | 50 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1999 | 679 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1996 | 198 | 0.010 |
Why?
|
| Insulin | 1 | 1999 | 1161 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1994 | 429 | 0.010 |
Why?
|